Why Haven't More Patients Been Treated With the Gene Therapies for Sickle Cell Disease? | AMCP Nexus 2024
It's not the multimillion dollar prices, says Kevin Niehoff, Pharm.D., of IPD Analytics. The pool of sickle cell disease patients who are prime candidates for sickle cell disease gene therapy was overestimated, according to Niehoff.
Approximately 100,000 people in the U.S. have one of group of inherited blood disorders that come under the heading of sickle cell disease. But that doesn’t make them all good candidate for one of the two FDA-approved gene therapies for sickle cell disease, Vertex’s Casgevy (exagamglogene autotemcel) and Bluebird Bio’s Lyfgenia (lovotibeglogene autotemcel), according to Kevin Niehoff, associate director at IPD Analytics and a panelist today at a session on sickle gene therapies at the 2024 Academy of Managed Care Pharmacy (AMCP) meeting in Las Vegas.
“Instead of having a potential patient pool of about 100,000 in the US, it's probably a lot closer to maybe 15,00 or 20,000,” Niehoff said in a video interview with Managed Healthcare Executive (MHE) prior to the meeting.
Niehoff told MHE that Vertex has reported that 20 patients had initiated treatment process that leads to treatment with Casgevy as of mid-2024 and that Bluebird Bio has reported that just four patients had started the arduous process that leads to treatment with Lyfgenia
Casgevy is priced at $2.2 miliom per treatment and Lyfgenia at $3.1 million. But Niehoff said he doesn’t see those high prices, which are borne by insurers, as reason for the low uptake. There are alternatives to gene therapy for patients with sickle cell disease, he noted, including stem cell transplants (sometimes called bone marrow transplants) that can be curative. Hydroxyurea can be used to treat the disease, said Niehoff, who also mentioned that sickle cell disease varies in severity.
“I think that the gene therapies are going to be used in patients that can't be controlled with existing therapies and don't have a [bone marrow] donor match,” Niehoff said.
Price, he said, is not as big a barrier to Casgevy and Lyfgnia “as where that therapy actually slots in."
Use of Copay Offset Programs Expected to Rise | AMCP Nexus 2024
October 15th 2024Just a small percentage of employers use alternative funding programs, including accumulators and maximizers. But approximately 60% of employers who do use these programs said in a survey they are effective at managing healthcare costs.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen
